This prospective observational cohort study evaluated genetic, immunologic, and environmental factors associated with type 1 diabetes in children. Children with newly diagnosed type 1 diabetes and their healthy siblings were enrolled between October 2017 and June 2021. Data collection included HLA class I and class II genotyping, measurement of diabetes-associated autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma-associated antigen-2 (IA-2A), zinc transporter 8 (ZnT8A), and islet cell antibodies (ICA), as well as C-peptide and glycated hemoglobin (HbA1c). Healthy siblings underwent annual follow-up assessments for three years, while children with type 1 diabetes were evaluated every three months during the first year after diagnosis. Information on environmental risk factors was collected using an investigator-developed questionnaire based on anamnestic data. The study aimed to identify biomarkers and risk factors associated with the development and progression of type 1 diabetes in children.
Type 1 diabetes is a chronic autoimmune disease resulting from immune-mediated destruction of pancreatic beta cells. Genetic susceptibility, autoimmune processes, and environmental exposures are believed to contribute to disease development and progression. This prospective observational cohort study included children with newly diagnosed type 1 diabetes and their healthy siblings. Participants were enrolled between October 2017 and June 2021. Baseline assessment included HLA class I and class II genotyping, measurement of diabetes-associated autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma-associated antigen-2 (IA-2A), zinc transporter 8 (ZnT8A), and islet cell antibodies (ICA), as well as C-peptide and glycated hemoglobin (HbA1c). Children with type 1 diabetes underwent follow-up clinical and laboratory assessments every three months during the first year after diagnosis. Healthy siblings underwent annual follow-up assessments for three years, including repeated evaluation of diabetes-associated autoantibodies, C-peptide, and glycated hemoglobin. HLA genotyping was performed only at baseline. Parents completed an investigator-developed questionnaire designed to collect anamnestic information on environmental risk factors for type 1 diabetes identified in the scientific literature. The questionnaire included data on prenatal and perinatal history, infant feeding practices, infectious diseases, family history, and other environmental exposures potentially associated with type 1 diabetes risk. Follow-up of healthy siblings continued until January 25, 2026, through telephone contact to determine whether type 1 diabetes had developed during the observation period. The collected data were used to evaluate associations among genetic, immunologic, laboratory, and environmental factors and to identify biomarkers associated with the risk and progression of type 1 diabetes in children.
Study Type
OBSERVATIONAL
Enrollment
1,034
Privolzhsky Research Medical University
Nizhny Novgorod, Nizhny Novgorod Oblast, Russia
Development of a Prediction Model for Type 1 Diabetes in Healthy Siblings
Development of a prediction model for type 1 diabetes based on HLA class I and class II genotypes, diabetes-associated autoantibodies (IAA, GADA, IA-2A, ZnT8A, and ICA), C-peptide, glycated hemoglobin (HbA1c), and environmental risk factors in healthy siblings of children with type 1 diabetes.
Time frame: Up to January 25, 2026
Development of Type 1 Diabetes in Healthy Siblings
Occurrence of type 1 diabetes among healthy siblings during follow-up.
Time frame: October 2017 to January 25, 2026
Diabetes-Associated Autoantibody Profile
Assessment of diabetes-associated autoantibodies (IAA, GADA, IA-2A, ZnT8A, and ICA) in children with type 1 diabetes and their healthy siblings.
Time frame: Up to 3 years
HLA Class I and Class II Genotypes
Assessment of HLA class I and class II genotypes associated with susceptibility to type 1 diabetes.
Time frame: Baseline
C-Peptide and Glycated Hemoglobin (HbA1c)
Assessment of endogenous insulin secretion and glycemic status using C-peptide and glycated hemoglobin measurements.
Time frame: Up to 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.